SPYCHIPPED LEVI'S BRAND JEANS HIT THE U.S.

By Liz McIntyre & Katherine Albrecht

April 19, 2006
http://www.NewsWithViews.com

It may be time to ditch your Dockers and lay off the Levi's, say privacy activists Katherine Albrecht and Liz McIntyre. New information confirms that Levi Strauss & Co. is violating a call for a moratorium on item-level RFID by spychipping its clothing. What's more, the company is refusing to disclose the location of its U.S. test.

Radio Frequency Identification (RFID) is a controversial technology that uses tiny microchips to track items from a distance. These RFID microchips have earned the nickname "spychips" because each contains a unique identification number, like a Social Security number for things, that can be read silently and invisibly by radio waves. Over 40 of the world's leading privacy and civil liberties organizations have called for a moratorium on chipping individual consumer items because the technology can be used to track people without their knowledge or consent.

Jeffrey Beckman, Director of Worldwide and U.S. Communications for Levi Strauss, confirmed his company's chipping program in an email exhange with McIntyre, saying "a retail customer is testing RFID at one location [in the U.S.]...on a few of our larger-volume core men's Levi's jeans styles." However, he refused to name the location.

Read Full Article here: www.newswithviews.com/McIntyre/Liz4.htm

Biotech Drug Disaster Underlies Danger of GE Pharma Crops

A drug trial catastrophe reflects upon the
secretive open field testing of pharm crops

This week saw the report of a drug trial that led to catastrophic injury to human volunteers. Six volunteers were injured , one of whom, may face up to a year or more of coma. The drug being tested (TGN 1412) was a recombinant humanized monoclonal antibody being developed to treat
diseases including leukemia and arthritis. The tests of the drug were being undertaken in Britain by a German biotechnology company (TeGenero).. The six young men participating in the drug trial were healthy volunteers paid a small fee to participate in the experiment(1,2,3,4). The Mab and its properties were described in a paper published in 2003, The drug is described as a superagonist (a super activator) of T-cells. The drug is expected to lead to development of
T-cell stimulatory drugs (5). T-cells are - a small lymphocyte developed in the thymus; they orchestrate the immune system's response to infected or malignant cells. The drug trial went wrong after a single relatively high dose led to over stimulation of the immune system leading to
inflammation and organ destruction.

Presently 18 Mab drugs have been approved by the US FDA. There are over 355 Mab drugs in clinical development. The drugs approved currently are mainly for cancer treatment and control of the immune system with a single anti-viral Mab. The approvals have been received by both
traditional pharmaceutical corporations and by biotechnology companies of relatively recent origin (6). Problems associated with the development of Mab drugs are widely recognized. A drug approved for treating multiple sclerosis (MS) was associated with several deaths from
brain infections. The drug was believed to block immune cell migration to the brain allowing virus infection. That drug has been voluntarily suspended for further study. The problem associated with up-regulating the immune system include inflammation of the eye, skin, gut, pituitary gland along with cases of hepatitis and loss of skin pigmentation(7). A humanized Mab used to treat colon cancer caused 17% of the cancer patients to experience adverse immune events . However, the initiation of adverse events could be detected by preliminary low level treatment and those patients could be removed from further treatment prior to the onset of severe adverse events(8). In the German human study in Britain a single high dose of Mab was reportedly used leading to adverse immune response (inflammation and organ failure) in all of those treated. In that experiment animal studies had been done but those experiments alone
are not sufficient to pinpoint all of the many problems associated with Mabs drug therapy. Adverse effects of the drug at low levels in one or two human subjects should have been studied before the whole group was exposed to high levels of the drug.

Full article: www.organicconsumers.org/ge/danger060323.cfm

Yucca Fool Some of the People Some of the Time

Feds won't press charges against scientists who falsified Yucca documents

Scientists accused of falsifying quality-assurance documents for the proposed Yucca Mountain nuclear-waste site in Nevada will not be charged by federal prosecutors. Emails between U.S. Geological Survey hydrologists from 1998 to 2000 indicate that dates were invented and inconvenient data was deleted as hydrologists conducted a data review before the Energy Department sought a license for the nuke-waste dump. The White House is pushing to speed up construction at Yucca, which is supposed to store 77,000 tons of waste from nuclear power plants. Despite the decision not to file charges, the Energy Department's inspector general admitted that the scientists' lapse has "had the effect of undermining public confidence in the quality of the science associated with the Yucca Mountain Project." Because that confidence was sky-high before, don't you know.

straight to the source: The Salt Lake Tribune, Robert Gehrke, 26 Apr 2006
straight to the source: Bloomberg, Tina Seeley, 25 Apr 2006

A great website on the nuclear waste issue: http://iratiwanti.org/home.php3

FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service

AIDS MAY BE A COMBINATION OF NUTRITIONAL DEFICIENCIES

HIV Depletes Body of Selenium and Three Amino Acids (OMNS, April 26, 2006)

New clinical reports from Zambia, Uganda and South Africaindicate that AIDS may be stopped by nutritional supplementation. A number of members of the medical profession have observed that high doses of the traceelement selenium, and of the amino acids cysteine, tryptophan, and glutamine cantogether rapidly reverse the symptoms of AIDS, as predicted by Dr. Harold D.Foster's nutritional hypothesis. (1)

These nutrients are necessary for the human body to produce the enzymeglutathione peroxidase. This enzyme is strongly antiretroviral (it is anantagonist of reverse transcriptase) and can greatly reduce HIV replication. Unfortunately, HIV has developed the ability to compete with the body for these four nutrients because shortages of them allow its more effective replication. Specifically, HIV has a gene that allows it to produce an analogue of glutathione peroxidase.

Diets high in selenium, cysteine, tryptophan and glutamine seem to have two major benefits for AIDS patients:

1) They replace these four nutrients in the body, correcting the deficiencies HIV has caused. AIDS is what we call these combined deficiency symptoms.

2) High levels of these four key nutrients push up the body's glutathione peroxidase levels, making it much more difficult for HIV to replicate. This enzyme also beneficially interferes with the replication of Hepatitis B and C. Nutritionally treated patients are still HIV-positive, but seem to generally remain in good health unless they start to eat a diet that once again is poor inone or more of these nutrients. If this occurs, glutathione peroxidase levels fall, HIV begins to be replicated and the AIDS cycle begins again.

Some countries or regions, like Senegal and Bolivia, have been very fortunate. Their bedrock is naturally elevated in selenium and their diets are normally high in the three amino acids. As a result, they are rarely infected by HIV. Others, like Finland, have wisely mandated the addition of selenium to their fertilizers, with similar results. In contrast, some regions like Kwazulu Natal have bedrock and soils that contain little selenium and diets are poor in one or more of the key nutrients. For example, corn (maize) is low in both selenium and tryptophan. As a result, populations eating a great deal of corn are easy toinfect with HIV and die very quickly of its associated nutritional deficiencies (AIDS).

To halt AIDS, to stop HIV from replicating, the needed nutrient levels are high. Selenium, for example, is taken at several times the commonly recommended dailyallowance for the first month. Dosage is considered in more detail in "What Really Causes AIDS." (2) This book is available for free reading and downloading at www.hdfoster.com.

What is Orthomolecular Medicine?
Linus Pauling defined orthomolecular medicine as "the treatment of disease by the provision of the optimum molecular environment, especially the optimum concentrations of substances normally present in the human body." Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

The peer-reviewed Orthomolecular Medicine News Service is a non-profit andnon-commercial informational resource.

Editorial Review Board:
Abram Hoffer, M.D., Ph.D.
Harold D. Foster, Ph.D.
Bradford Weeks, M.D.
Carolyn Dean, M.D. N.D.
Erik Paterson, M.D.
Thomas Levy, M.D.,
J.D.Steve Hickey, Ph.D.
Andrew W. Saul, Ph.D., Editor. Email: omns@orthomolecular.org

References:

1. Foster HD. How HIV-1 causes AIDS: Implications for prevention and treatment,"Medical Hypotheses, Vol. 62(4), p 549-553, 2004.

2. Foster HD. What really causes AIDS. Victoria, BC: Trafford, 2002. Freedownload at www.hdfoster.com.

For further reading:"HIV/AIDS: a nutrient deficiency disease," Journal of Orthomolecular Medicine,2005, Vol. 20(2), p 67-69. Environmental factors and the pathogenesis of selenium-CD-4 cell tailspin in AIDS. Chinese Journal of AIDS and STD, Vol. 10(5), p 390-392,402 2004.

AIDS and the selenium-CD4T cell tailspin," World Journal of Infection, Vol.3(6), p 456-459, 2003. Micronutrients in pathogenesis and treatment of AIDS," Foreign Medical Sciences:Section of Medgeography, Vol. 24(2), p 49-53, 2003.

Why HIV-1 has diffused so much more rapidly in Sub-Saharan Africa than in NorthAmerica. Medical Hypotheses, Vol. 60(4), p 611-614, 2003.

"How HIV-1 kills: Implications for the treatment and prevention of AIDS.Townsend Letter for Doctors and Patients, No. 255, p 76-78, 2002.

"Aids and the 'selenium - CD4T cell tailspin': the geography of a pandemic,"Townsend Letter for Doctors and Patients, No. 209, p 94-99, 2000.